HER2 Expression in Salivary Gland Carcinomas: Dependence on Histological Subtype

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 944-946

  Glisson, Bonnie ^a   Colevas, A Dimitrios ^b,f   Haddad, Robert ^b   Krane, Jeoffrey ^b   El Naggar, Adel ^a   Kies, Merrill ^a   Costello, Rosemary ^b   Summey, Carmen ^a   Arquette, Matthew ^c   Langer, Corey ^d   Amrein, Philip C ^e   Posner, Marshall ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADENOID CYSTIC CARCINOMA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; HISTOGENESIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; TUMOR CELL;

ANTIBODIES, MONOCLONAL; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; TUMOR MARKERS, BIOLOGICAL;

EID: 10744227930     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0253     Document Type: Article

References (18)

1. Spiro, R. H. Management of malignant tumors of the salivary glands. Oncology, 12: 671-680, 1988.
2. Batsakis, J. G., Regez, J. A., Luna, M. A., and El-Naggar, A. C. Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol. Otol., 103: 939-944, 1989.
3. Dardick, I., and Van Nostrand, P. Morphogenesis of salivary gland tumors: a prerequisite to improving classification. Pathology Annual, 22: 1-53, 1987.
4. Creagan, E. T., Woods, J. E., Schutt, A. J., and O'Fallon, J. R. Cyclophosphamide, Adriamycin, and cis-diamminedichloroplatinum(II) in the treatment of advanced nonsquamous cell head and neck cancer. Cancer (Phila.), 52: 2007-2010, 1983.
5. Dreyfuss, A. I., Clark, J. R., Fallon, B. G., Posner, M. R., Norris, C. M., Jr., and Miller, D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer (Phila.), 60: 2869-2872, 1987.
6. Venook, A. P., Tseng, A., Jr., Meyers, F. J., Silverberg, I., Boles, R., Fu, K. K., and Jacobs, C. D. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J. Clin. Oncol., 5: 951-955, 1987.
7. Airoldi, M., Pedani, F., Succo, G., Gabriele, A. M., Ragona, R., Marchionatti, S., and Bumma, C. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with current salivary gland malignancies. Cancer (Phila.), 91: 541-547, 2001.
8. Jennings, T., Li, Y., Pinto, H., Kies, M., Mansour, E., and Foratsiere, A. Phase II trial of paclitaxel in advanced or metastatic salivary gland malignancies: an Eastern Cooperative Oncology Group Study. Proc. Am. Soc. Clin. Oncol., 20: 236a, 2001.
9. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash. DC), 230: 1132-1139, 1985.
10. Prenzel, N., Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer, 8: 11-31, 2001.
11. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
12. Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol., 11: 1936-1942, 1993.
13. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
14. Giannoni, C., El-Naggar, A. K., Ordnoez, N. G., Tu, Z. N., Austin, J., Luna, M. A., and Batsakis, J. G. C-erbB-2/neu oncogene and Ki67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol. Head Neck Surg., 112: 391-398, 1995.
15. Shintani, S., Funayama, T., Yoshihama, Y., Alcalde, R. E., Ootsuki, K., Terakado, N., and Matsumura, T. Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res., 15: 2623-2626, 1995.
16. Khan, A. J., Digiovanna, M. P., Ross, D. A., Sasaki, C. T., Carter, D., Son, Y. H., and Haffty, B. G. Adenoid cystic carcinoma: a retrospective clinical review. Int. J. Cancer, 96: 149-158, 2001.
17. Press, M. F., Pike, M. C., Hung, G., Zhou, J. Y., Ma, Y., George, J., Dietz-Band, J., James, W., Slamon, D. J., Batsakis, J. G., and El-Naggar, A. K. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res., 54: 5675-5682, 1994.
18. Haddad, R. I., Colevas, A. D., Glisson, B. S., Krane, J., Cooper, D., Amrein, P., Costello, R., Weeks, L., and Posner, M. R. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol., 39: 724-727, 2003.